Macrogenics (MGNX)

$1.75 0.00 (N/A)
Market Cap 115.76M
Revenue (ttm) 149.96M
Net Income (ttm) -66.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -44.66%
Debt to Equity Ratio 0.00
Volume 548,500
Avg Vol 1,420,022
Day's Range N/A - N/A
Shares Out 63.26M
Stochastic %K 38%
Beta 1.51
Analysts Sell
Price Target $3.40

Company Profile

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which ha...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 251 5172
Fax: 301 251 5321
Address:
9704 Medical Center Drive, Rockville, United States
MarketWarfare
MarketWarfare Jan. 30 at 3:53 PM
$MGNX stock was primed and ready to go and management failed to deliver as usual. I've never seen a biotech release LESS news than this company. All the recent gains wiped out in a second on no volume.
0 · Reply
PSDL75
PSDL75 Jan. 30 at 3:32 PM
$MGNX you spoke this into existence
1 · Reply
Budman10
Budman10 Jan. 29 at 9:12 PM
$MGNX this action seems similar to what happened the last time an institution was dumping. We went up to this level then came back down to $1.50 Hopefully its it’s different this time
1 · Reply
PSDL75
PSDL75 Jan. 29 at 5:01 PM
$MGNX so forgotten it gets not one comment on a 6% move against the market....
2 · Reply
Hawaiianstockguru
Hawaiianstockguru Jan. 27 at 8:54 AM
$MGNX say something 8m giving up on
0 · Reply
RunnerSignals
RunnerSignals Jan. 22 at 10:13 PM
golden cross watch $MGNX $NBTB $PBR $ZD lighting up with buy signals flashing
0 · Reply
Budman10
Budman10 Jan. 22 at 9:40 PM
$MGNX Big sales end of the day. Wondering if another institution is unloading
0 · Reply
MarketWarfare
MarketWarfare Jan. 22 at 9:15 PM
$MGNX never any news to support this stock. New CEO is a turd just like the old one.
0 · Reply
PSDL75
PSDL75 Jan. 22 at 9:02 PM
$MGNX
0 · Reply
PSDL75
PSDL75 Jan. 22 at 8:58 PM
$MGNX well, good news is I bought a ton at $1.65... wonder what that was
1 · Reply
Latest News on MGNX
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 4:05 PM EST - 2 months ago

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Nov 12, 2025, 4:01 PM EST - 2 months ago

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

MacroGenics to Participate in the Stifel 2025 Healthcare Conference

Nov 6, 2025, 4:30 PM EST - 3 months ago

MacroGenics to Participate in the Stifel 2025 Healthcare Conference

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:30 PM EDT - 5 months ago

MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

Aug 14, 2025, 4:01 PM EDT - 6 months ago

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

Aug 13, 2025, 4:01 PM EDT - 6 months ago

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

MacroGenics: Working On That Road To Recovery

Jun 11, 2025, 6:32 PM EDT - 8 months ago

MacroGenics: Working On That Road To Recovery

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

Jun 10, 2025, 7:00 AM EDT - 8 months ago

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 3, 2025, 4:30 PM EDT - 8 months ago

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 13, 2025, 4:01 PM EDT - 9 months ago

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

MacroGenics Announces Date of First Quarter 2025 Financial Results

May 6, 2025, 4:30 PM EDT - 9 months ago

MacroGenics Announces Date of First Quarter 2025 Financial Results

MacroGenics to Participate in Upcoming Investor Conference

May 1, 2025, 4:30 PM EDT - 9 months ago

MacroGenics to Participate in Upcoming Investor Conference

MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:09 PM EDT - 11 months ago

MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

Mar 6, 2025, 7:30 AM EST - 11 months ago

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

MacroGenics: Stacking Up A Lot Of Headwinds

Feb 27, 2025, 2:08 PM EST - 1 year ago

MacroGenics: Stacking Up A Lot Of Headwinds

MacroGenics to Participate in Upcoming Investor Conferences

Feb 27, 2025, 7:30 AM EST - 1 year ago

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript

Nov 5, 2024, 7:01 PM EST - 1 year ago

MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

Nov 5, 2024, 4:01 PM EST - 1 year ago

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

MacroGenics Announces Leadership Transition

Oct 30, 2024, 7:30 AM EDT - 1 year ago

MacroGenics Announces Leadership Transition

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

Oct 29, 2024, 4:30 PM EDT - 1 year ago

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders

Oct 25, 2024, 5:15 PM EDT - 1 year ago

Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

Oct 22, 2024, 7:30 AM EDT - 1 year ago

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX

Sep 24, 2024, 12:57 PM EDT - 1 year ago

Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX

MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm

Sep 24, 2024, 10:30 AM EDT - 1 year ago

MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

Sep 23, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman

Sep 22, 2024, 11:09 AM EDT - 1 year ago

MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Reach Out To The Schall Law Firm

Sep 21, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Reach Out To The Schall Law Firm

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders Are Urged To Contact The Schall Law Firm

Sep 19, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders Are Urged To Contact The Schall Law Firm

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics

Sep 19, 2024, 9:57 AM EDT - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNX

Sep 19, 2024, 5:45 AM EDT - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNX

MGNX Deadline: Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Sep 17, 2024, 11:23 AM EDT - 1 year ago

MGNX Deadline: Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Hospice Dynamix Welcomes Industry Veteran Rob Stoltz as Chief Strategy Officer

Sep 17, 2024, 11:04 AM EDT - 1 year ago

Hospice Dynamix Welcomes Industry Veteran Rob Stoltz as Chief Strategy Officer

MacroGenics Inc May Have Violated Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm About A Suit

Sep 17, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc May Have Violated Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm About A Suit

Investor Reminder (MGNX):  Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc.  Investors of September 24, 2024 Deadline

Sep 16, 2024, 12:14 PM EDT - 1 year ago

Investor Reminder (MGNX):  Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc.  Investors of September 24, 2024 Deadline

MarketWarfare
MarketWarfare Jan. 30 at 3:53 PM
$MGNX stock was primed and ready to go and management failed to deliver as usual. I've never seen a biotech release LESS news than this company. All the recent gains wiped out in a second on no volume.
0 · Reply
PSDL75
PSDL75 Jan. 30 at 3:32 PM
$MGNX you spoke this into existence
1 · Reply
Budman10
Budman10 Jan. 29 at 9:12 PM
$MGNX this action seems similar to what happened the last time an institution was dumping. We went up to this level then came back down to $1.50 Hopefully its it’s different this time
1 · Reply
PSDL75
PSDL75 Jan. 29 at 5:01 PM
$MGNX so forgotten it gets not one comment on a 6% move against the market....
2 · Reply
Hawaiianstockguru
Hawaiianstockguru Jan. 27 at 8:54 AM
$MGNX say something 8m giving up on
0 · Reply
RunnerSignals
RunnerSignals Jan. 22 at 10:13 PM
golden cross watch $MGNX $NBTB $PBR $ZD lighting up with buy signals flashing
0 · Reply
Budman10
Budman10 Jan. 22 at 9:40 PM
$MGNX Big sales end of the day. Wondering if another institution is unloading
0 · Reply
MarketWarfare
MarketWarfare Jan. 22 at 9:15 PM
$MGNX never any news to support this stock. New CEO is a turd just like the old one.
0 · Reply
PSDL75
PSDL75 Jan. 22 at 9:02 PM
$MGNX
0 · Reply
PSDL75
PSDL75 Jan. 22 at 8:58 PM
$MGNX well, good news is I bought a ton at $1.65... wonder what that was
1 · Reply
Henry20feb_
Henry20feb_ Jan. 21 at 9:43 PM
$MGNX According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, MacroGenics, Xencor, Merck & Co., Pfizer, Bristol-Myers Squibb (BMS), Candid Therapeutics, Cullinan Therapeutics and others.
0 · Reply
Henry20feb_
Henry20feb_ Jan. 18 at 11:52 AM
$MGNX This one with MGNX logo!
1 · Reply
Henry20feb_
Henry20feb_ Jan. 18 at 11:38 AM
$MGNX
0 · Reply
DylanGFM
DylanGFM Jan. 16 at 6:33 PM
$CELZ $MGNX $MTC $MSGM on watch for retest of previous highs on upcoming continuations
0 · Reply
MarketWarfare
MarketWarfare Jan. 15 at 7:15 PM
$MGNX stock just languishes... forever.. no pulse, nothing.
1 · Reply
Budman10
Budman10 Jan. 14 at 2:31 PM
$MGNX Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
0 · Reply
Selfmademan
Selfmademan Jan. 12 at 6:46 PM
$CTMX kinda like $MGNX except ctmx keeps their best asset(s) to themselves. Mgnx gave away Tzield & Zynyz for peanuts. Varseta-M will go to someone else but peanuts wont be on the menu.
0 · Reply
Budman10
Budman10 Jan. 7 at 9:15 PM
$MGNX Nice to see the positive move today. Let’s hope no other institution decides to exit. Been too many of them this year. They have apparently lost confidence in management as well.
0 · Reply
AaronBobDale
AaronBobDale Jan. 7 at 4:25 PM
$MGNX terrific! I have much time for you MGNX! All the way back up let’s go
0 · Reply
SMARTR8
SMARTR8 Jan. 7 at 2:47 PM
$MGNX solid from 1.35 ✅️🤝
0 · Reply
Budman10
Budman10 Jan. 7 at 2:19 AM
$MGNX Ok tonight a 13 D (complete exit of investment in) was filed by the Bellevue Group AG. they have sold out of their entire position of approx. 10 million shares. they owned 15% of MGNX in 2025. Explains all the funny trading. Hopefully the selling pressure is done now.
0 · Reply
Budman10
Budman10 Jan. 5 at 6:43 PM
$MGNX Tzield news today Sanofi SNY announced that the FDA has accepted a regulatory filing seeking to expand the use of its type 1 diabetes (T1D) drug, Tzield (teplizumab), in individuals aged one year and older. The agency has granted priority review to this filing, with a final decision expected by April 29, 2026. Potential Future Milestones: MacroGenics is still eligible to receive additional milestone payments from Sanofi, potentially up to another $50 million if TZIELD achieves a certain level of net sales. They remain eligible for up to $379.5 million in total additional development, regulatory, and commercial milestones related to the drug. Royalty Share: MacroGenics retains the right to a 50% share of the royalty on global net sales of TZIELD, but only above a certain annual sales threshold
0 · Reply